CA2165344A1 - Immune stimulants in bacterial infections - Google Patents

Immune stimulants in bacterial infections

Info

Publication number
CA2165344A1
CA2165344A1 CA002165344A CA2165344A CA2165344A1 CA 2165344 A1 CA2165344 A1 CA 2165344A1 CA 002165344 A CA002165344 A CA 002165344A CA 2165344 A CA2165344 A CA 2165344A CA 2165344 A1 CA2165344 A1 CA 2165344A1
Authority
CA
Canada
Prior art keywords
alkyl
group
phenyl
alkoxy
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002165344A
Other languages
English (en)
French (fr)
Inventor
Peter C. Canning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2165344A1 publication Critical patent/CA2165344A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002165344A 1993-06-15 1994-04-26 Immune stimulants in bacterial infections Abandoned CA2165344A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7784693A 1993-06-15 1993-06-15
US08/077,846 1993-06-15
US12210893A 1993-09-16 1993-09-16
US08/122,108 1993-09-16
PCT/IB1994/000082 WO1994028898A1 (en) 1993-06-15 1994-04-26 H2-antagonists as immune stimulants in bacterial infections of cattle or swine

Publications (1)

Publication Number Publication Date
CA2165344A1 true CA2165344A1 (en) 1994-12-22

Family

ID=26759749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002165344A Abandoned CA2165344A1 (en) 1993-06-15 1994-04-26 Immune stimulants in bacterial infections

Country Status (7)

Country Link
EP (1) EP0703782A1 (xx)
JP (1) JPH08506353A (xx)
AU (1) AU6436394A (xx)
CA (1) CA2165344A1 (xx)
HU (1) HUT70766A (xx)
IL (1) IL109953A0 (xx)
WO (1) WO1994028898A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
CN110237075A (zh) * 2019-06-25 2019-09-17 华中农业大学 一种达氟沙星在治疗副猪嗜血杆菌药物中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4435396A (en) * 1982-05-10 1984-03-06 Pfizer Inc. Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor
US4560690A (en) * 1984-04-30 1985-12-24 Pfizer Inc. 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents
US4636498A (en) * 1984-10-11 1987-01-13 Pfizer Inc. Formulation of antiinflammatory drugs
US4591595A (en) * 1984-10-11 1986-05-27 Pfizer Inc. 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis

Also Published As

Publication number Publication date
HUT70766A (en) 1995-10-30
JPH08506353A (ja) 1996-07-09
HU9401775D0 (en) 1994-09-28
EP0703782A1 (en) 1996-04-03
IL109953A0 (en) 1994-10-07
AU6436394A (en) 1995-01-03
WO1994028898A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
US7396825B2 (en) Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
AU2014372166B2 (en) Pharmaceutical combinations
US20090181920A1 (en) Intrathecal treatment of neuropathic pain with a2ar agonists
US8492383B2 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
MX2008008723A (es) Tratamiento de la hepatitis viral.
EA028434B1 (ru) Лечение рака ингибиторами tor киназы
PL209733B1 (pl) Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych
CA3034258A1 (en) Ppar.gamma. agonist for treatment of blood cancers
US20220323436A1 (en) Protein kinase c inhibitors for treatment of uveal melanoma
CA2165344A1 (en) Immune stimulants in bacterial infections
CN114144180A (zh) 治疗胆管癌的方法
EP2754441B1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
US11931344B2 (en) Sphingosine pathway modulating compounds for the treatment of coronavirus infection
JP2005500303A (ja) ヒト成長ホルモンアンタゴニスト
Khalil et al. Ceftiofur pharmacokinetics in Nile tilapia Oreochromis niloticus after intracardiac and intramuscular administrations
EP1296665B1 (en) Analgesic and anti-inflammatory compositions containing celecoxib and ibuprofen
HU230366B1 (hu) Kinurénsavamid származékok alkalmazása Huntington-kór kezelésére
US20080096864A1 (en) Treatment Of Gastrointestinal Stromal Tumors With Imatinib And Midostaurin
KR20140107416A (ko) 제i형 및 제ii형 당뇨병의 치료
JPH03502802A (ja) 抗嘔吐性エルゴリン誘導体
TW202329969A (zh) 用於治療急性髓系白血病的ＦＬＴ３抑制劑和Ｂｃｌ－３抑制劑的治療有效組合
CN117396202A (zh) 给药方案
KR20240149878A (ko) 위암을 치료하는데 사용하기 위한 화합물
JPS59144718A (ja) マイコプラズマ感染症治療予防剤
US20140235581A1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued